Reference
Arthurs E, et al. Dolutegravir and Rilpivirine to Treat Virologically Suppressed Adults Living with HIV-1: a Canadian Cost-Utility Analysis. 23rd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : (plus oral presentation) abstr. AV3, 19 May 2018. Available from: URL: https://www.ispor.org/ScientificPresentationsDatabase/Presentation/80978?pdfid=53675
Rights and permissions
About this article
Cite this article
Dolutegravir/rilpivirine cost effective for HIV-1 in Canada. PharmacoEcon Outcomes News 805, 14 (2018). https://doi.org/10.1007/s40274-018-5016-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5016-x